An interventional study of Prehabilitation in Risk Reduction, Urological Cancer and Surgery, sponsored by Bispebjerg Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Bispebjerg Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Despite knowledge about the effect of preventive measures in lifestyle, smoking,nutrition, alcohol and physical activity (SNAP), there is a lack of systematic assessment of the overall lifestyle of the patient before surgery and knowledge about how lifestyle interventions can be organized in connection with cancer surgery. The intention with prehabilitation is to optimize the individual's risk factors and personal burdens that can affect the clinical and patient reported outcomes after surgery. The aim of this study is to evaluate the efficacy of intensive SNAP interventions compared to treatment as usual (TAU) in ptt undergoing urological cancer surgery on surgical risk reduction.
The project contains three clinical intervention studies, in total including 100 urological cancer patients screened positive for at least 1 SNAP factor:
I. Efficacy and preferences of intensive SNAP-Interventions among patients with at least one SNAP factor and undertaking neo-adjuvant chemotherapy before radical cystectomy. A randomised controlled trial with nested interviews (42 patients).
II. Implementation and preferences of intensive SNAP-Interventions among patients with kidney cancer undergoing nephrectomy/partial nephrectomy. An implementation feasibility study including interviews (20 patients).
III. Reach out and effect as well as preferences of perioperative intensive smoking cessation intervention via the municipality clinic compared to the surgical department among smokers with non-invasive bladder cancer treated with Trans-Urethral Resection of the Bladder (TUR-B). A randomised controlled trial with nested interviews (38 patients).
The intervention groups receive minimum five educational sessions tailored to individual needs over six weeks perioperatively. The control groups receive standard care.
291 studies on the registry are indexed under Risk Reduction Behavior; 38 are open to participants now.
This study's planned enrollment of 100 is below the median of 201 across 250 interventional studies indexed under Risk Reduction Behavior.
Browse Risk Reduction Behavior studies →Bispebjerg Hospital is the lead sponsor of 289 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
Behavioral: Prehabilitation
Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
Also known as: smoking cessation, alcohol cessation, physical activity, nutritional support for malnutrition and obesity
Number of patients with risk reduction at surgery
Corresponding at least 1 step for 1 or more risky lifestyles (but only smoking in study III) on the ASA-score (American Society of Anaesthesiologists physical status classification from 1-5, lower is better)
Time frame: End of intervention/ at surgery
Health related quality of life (HRQoL)
Mean difference of HRQoL between groups measured with EQ5D (5 level quality of life score (level 1 =no problems, level 2-5 =problems)
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients with any postoperative complication
Scored by the Comprehensive Complication Index, a linear scale ranging from 0 (no complication) to 100 (death)
Time frame: 30 days
Number of successful tobacco quitters
Successful quitting smoking: Study I+ II+ III * Successful quitting alcohol intake at 6 weeks and below risky limits at 6 months: Study I. * Physical activity at least 30 minutes per day: Study I. * Malnutrition: Not at risk of malnutrition: Study I. Obesity: 5% -10 % loss of body fat mass and below 1% gain of body fat mass at 6 months (without developing malnutrition)
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of successful alcohol quitters
Successful quitting alcohol: Study I+II
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients being physical active at least 30 min per day
Minutes physical active measured by an accelerometer (longer time is better) : Study I+II
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients not at risk of malnutrition
NRS2002 (Nutritional Risk Screening 2002) score\>2. Lower is better: Study I+II
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients not at risk of obesity
BMI (Body Mass Index)\<30. Lower is better : Study I+II
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients with improved frailty level
Measured by Lammers definition: Lower is better: Study I+II+III
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Number of patients with any reduction in lifestyle
Measured by yes/no. Study I+II+III
Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months
Started Jan 2022 (actual). Primary completion is estimated for Jun 2025, 41 months after the start.
Of 167 non-industry interventional studies with no phase under Risk Reduction Behavior, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 41 months is above that.
Counting every sponsor, half of 169 studies reached it within 25 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.